AstraZeneca|Merck''s Lynparza shows survival benefit in ovarian cancer patients in long-term data
AstraZeneca (AZN) and Merck (MRK) Lynparza said their drug Lynparza showed clinically meaningful survival benefit as first line therapy in certain patients with ovarian cancer as…
AstraZeneca|Merck''s Lynparza shows survival benefit in ovarian cancer patients in long-term data
AstraZeneca (AZN) and Merck (MRK) Lynparza said their drug Lynparza showed clinically meaningful survival benefit as first line therapy in certain patients with ovarian cancer as…